Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.

Nicholas B FiguraWendy LongMichael YuTimothy J RobinsonSepideh MokhtariArnold B EtameNam D TranRoberto DiazHatem SolimanHeather S HanSolmaz SahebjamPeter A ForsythKamran A Ahmed

Published in: Breast cancer research and treatment (2018)

IT trastuzumab was well tolerated with prolongation of OS over historical controls. IT trastuzumab should be considered for management of HER2+ leptomeningeal disease patients.

Keyphrases

epidermal growth factor receptor
end stage renal disease
metastatic breast cancer
newly diagnosed
ejection fraction
chronic kidney disease
cerebrospinal fluid
prognostic factors
peritoneal dialysis
small cell lung cancer
patient reported outcomes
brain metastases
drug induced